NASDAQ: TRAXFirst Tracks Biotherapeutics Inc Stock
$18.60
Updated Apr 20, 2026
TRAX Price
$18.60
Fair Value Price
N/A
Market Cap
N/A
52 Week Low
$15.00
52 Week High
$21.00
P/E
N/A
P/B
N/A
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$166.09M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.15
Operating Cash Flow
-$143M
Beta
N/A
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
TRAX Overview
First Tracks Biotherapeutics, Inc. engages in the research and development of immunology therapeutics for autoimmune and inflammatory diseases. It focuses on clinical-stage programs for rosnilimab, ANB033 and ANB101. The company is headquartered in San Diego, CA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine TRAX's potential to beat the market
- TRAX doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Be the first to know about important TRAX news, forecast changes, insider trades & much more!
TRAX News
Overview
Due Diligence Score
–
Industry Average (29)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how TRAX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
TRAX's cash and short-term investments ($311.64M) can cover TRAX's cash burn for the next year (N/A), after accounting for decreasing cash burn (N/A)
Interest Coverage Financials
TRAX's short-term assets ($316.40M) exceed its short-term liabilities ($31.02M)
Short-term Liabilities Financials
TRAX's short-term assets ($316.40M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
There are 30 more TRAX due diligence checks available for Premium users.
Valuation
TRAX's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
TRAX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$330.5M
Liabilities
$43.1M
Debt to equity
0.15
TRAX's short-term assets ($316.40M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
TRAX's short-term assets ($316.40M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
TRAX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
TRAX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
First Tracks Biotherapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.